Corcept Therapeutics/$CORT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
- Ticker
- $CORT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 730
- Headquarters
- Redwood City, United States
- Website
- www.corcept.com
CORT Metrics
BasicAdvanced
$8.8B
178.81
$0.45
0.46
-
Price and volume
Market cap
$8.8B
Beta
0.46
52-week high
$126.38
52-week low
$28.66
Average daily volume
942K
Financial strength
Current ratio
2.859
Quick ratio
2.504
Long term debt to equity
0.011
Total debt to equity
0.013
Profitability
EBITDA (TTM)
8.084
Gross margin (TTM)
98.30%
Net profit margin (TTM)
6.64%
Operating margin (TTM)
0.77%
Effective tax rate (TTM)
-109.27%
Revenue per employee (TTM)
$1,140,000
Management effectiveness
Return on assets (TTM)
0.47%
Return on equity (TTM)
8.23%
Valuation
Price to earnings (TTM)
178.815
Price to revenue (TTM)
10.18
Price to book
12.4
Price to tangible book (TTM)
12.4
Price to free cash flow (TTM)
79.103
Free cash flow yield (TTM)
1.26%
Free cash flow per share (TTM)
1.025
Growth
Revenue change (TTM)
16.02%
Earnings per share change (TTM)
-59.30%
3-year revenue growth (CAGR)
24.73%
10-year revenue growth (CAGR)
29.22%
3-year earnings per share growth (CAGR)
-17.60%
10-year earnings per share growth (CAGR)
47.69%
What the Analysts think about CORT
Analyst ratings (Buy, Hold, Sell) for Corcept Therapeutics stock.
Analyst projections of the future price of Corcept Therapeutics stock.
Bulls say / Bears say
Lifyorli is already adding a second revenue stream: it generated $47.6 million in its first quarter on sale, with more than 1,300 patients starting treatment after its March approval. That gives Corcept a commercial foothold in ovarian cancer beyond its Cushing’s business. (Corcept Therapeutics)
The established Cushing’s business remains a growth engine: second-quarter Korlym and authorised-generic revenue rose to $208.6 million from $194.4 million a year earlier, and Corcept raised its 2026 revenue outlook to $1.1–$1.2 billion. This supports the view that growth is not reliant on the new oncology launch alone. (Corcept Therapeutics)
Relacorilant could gain a second indication in Cushing’s syndrome: Corcept has resubmitted its application with an FDA decision expected by 17 December 2026, and the company reports positive trial results with fewer certain treatment-related risks than existing options. Approval would widen the drug’s potential market beyond ovarian cancer. (Corcept Therapeutics, Corcept Therapeutics)
Relacorilant’s Cushing’s application has already been turned down once: the FDA said the initial submission did not provide enough evidence of efficacy to support approval. The resubmission remains under review, so this potential growth driver still carries material regulatory risk. (StockTitan)
Generic competition threatens the Korlym business that still supplies most revenue. A court ruling found Teva’s generic did not infringe Corcept’s patents, and the generic is already on the market, creating a risk of lower prices or lost sales. (StockTitan)
Higher spending is weighing on earnings despite revenue growth: operating expenses rose to $429.4 million in the first half of 2026 from $321.6 million a year earlier, leaving an operating loss of $8.3 million. Continued launch and commercial investment may limit the profit benefit from sales growth. (Corcept Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2026.
CORT Financial Performance
Revenues and expenses
CORT Earnings Performance
Company profitability
Upcoming events
No upcoming events
CORT News
AllArticlesVideos
Funds containing CORT
AllUSDEURGBP
Fund name | Fund size | $CORT weighting |
|---|---|---|
SPDR S&P 400 US Mid Cap$SPY4 | $6.4B | 0.23% |
SPDR S&P 400 US Mid Cap£SPX4 | $6.4B | 0.23% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.13% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.13% |
iShares MSCI World Small Cap£WLDS | $9B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.